IP Library Granted Patent US 9,931,388
Granted Patent B2
US 9,931,388 · App. 15/082,920 · Granted Apr 3, 2018

Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers

Inventors: Andrea Mahr (Tuebingen, DE); Toni Weinschenk (Aichwald, DE); Oliver Schoor (Tuebingen, DE); Jens Fritsche (Dusslingen, DE); Harpreet Singh (Munich, DE); Colette Song (Ostfildern, DE)
Assignee: IMMATICS BIOTECHNOLOGIES GMBH
A61K39/0011A61K35/17C07K14/4748C07K14/70539C07K16/18C07K16/2833C07K16/3038C12N5/0636C12N15/115G06F19/20A61K2035/124A61K2039/505A61K2039/5158A61K2039/572C07K14/705C07K2317/73C07K2317/76C07K2319/33C07K2319/55C12N2310/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,931,388
App. No.
15/082,920
Granted
Apr 3, 2018
Kind
B2
Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Claims (10)

1. A peptide consisting of the amino acid sequence of SEQ ID NO. 38 in the form of a pharmaceutical acceptable salt.

2. The peptide according to claim 1 , wherein said peptide is bound to an WIC class-I or II molecule, and wherein said peptide is capable of being recognized by CD4 and/or CD8 T cells.

3. The peptide according to claim 1 , wherein said peptide is modified and/or includes non-peptide bonds.

4. The peptide according to claim 1 , wherein said peptide is part of a fusion protein, and wherein the fusion protein optionally comprises N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii).

5. A kit comprising:

(a) a container comprising a pharmaceutical composition containing the peptide(s) according to claim 1 , in solution or in lyophilized form; and

(b) wherein the kit optionally comprises one or more of a buffer, a diluent, a filter, a needle, instructions for use of the solution or reconstitution and/or use of the lyophilized formulation, or a syringe.

6. A pharmaceutical composition comprising

a peptide consisting of SEQ ID NO. 38 in the form of a pharmaceutically acceptable salt.

7. The peptide of claim 1 , wherein said peptide is produced by solid phase peptide synthesis or produced by a yeast cell or bacterial cell expression system.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2017
From: MAHR, ANDREA; WEINSCHENK, TONI; SCHOOR, OLIVER; FRITSCHE, JENS; SINGH, HARPREET; SONG, COLETTE
To: IMMATICS BIOTECHNOLOGIES GMBH
Reel/Frame 042213/0482 →
Continuity (2)
Provisional Application 62140767 · Mar 31, 2015
Related Publication 20160289296A1 · Oct 6, 2016